共 50 条
- [1] An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS228 - TPS228Lenz, Heinz-JosefSomasundaram, AshwinLee, Michael SangminSohal, DavendraSafyan, Rachael A.Zhu, MojunJones, Jeremy CliftonBhansali, AdityaKalwar, RozaCho, MayGrothey, Axel
- [2] An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinomaANNALS OF ONCOLOGY, 2023, 34 : S34 - S35Elez, E.Shepard, D.Smolenschi, C.Bekaii-Saab, T.Jac, J.
- [3] An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Kim, KevinSaeed, AnwaarSohal, DavendraEdeline, JulienHeo, JeongBhansali, AdityaKumar, ShaheenUngerechts, Guy
- [4] A multicenter, open-label study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC).JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS649 - TPS649Kim, KevinSaeed, AnwaarIyer, RenukaKim, Richard D.Feun, Lynn G.Kumar, Shaheen
- [5] An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinomaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Bekaii-Saab, Tanios S.Yarchoan, MarkAhmed, MuneebCohan, David MichaelMa, Wen Wee
- [6] An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS576 - TPS576Kim, KevinSaeed, AnwaarSohal, DavendraEdeline, JulienHeo, JeongBhansali, AdityaKumar, ShaheenUngerechts, Guy
- [7] An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS623 - TPS623Bekaii-Saab, Tanios S.Yarchoan, MarkAhmed, MuneebCohan, David MichaelMa, Wen Wee
- [8] A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neckJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Harrington, Kevin JosephCohen, EzraZandberg, Dan PaulDay, Terry A.Geiger, Jessica LynOliva, MarcMesia, RicardCohan, David Michael
- [9] An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Harrington, Kevin JosephRullan, AntonioDeighton, LouiseBarata, JoaoCastro, HenryAhlers, Christoph MatthiasMcrae, JohnBommareddy, PraveenCoffin, Robert S.Middleton, Mark R.
- [10] Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Si, LuFang, MeiyuChen, YuMao, LiliZhang, PengLin, JingBai, XueCao, XiaoChen, YiGuo, Jun